Scribe Therapeutics Prices Upsized IPO Amid CRISPR Technology Surge

Scribe Therapeutics has officially priced its upsized initial public offering at $15.00 per share, marking a significant milestone for the clinical-stage biotechnology company. The offering consists of 8,580,000 shares, with the firm anticipating gross proceeds of approximately $128.7 million before accounting for underwriting discounts and expenses. Scribe, which trades on the Nasdaq under the symbol SCTX, has also provided underwriters a 30-day option for an additional 1,287,000 shares to meet anticipated investor demand, with shares slated to begin trading today, July 24, 2026.

The company is advancing purpose-built in vivo CRISPR technologies, with its primary focus on cardiometabolic diseases such as elevated LDL-C and triglycerides. A concurrent private placement of 500,000 shares at the same $15.00 price to Sanofi further underscores the industry's confidence in Scribe’s CRISPR by Design platform. By epigenetically silencing the PCSK9 gene without altering permanent DNA, Scribe aims to establish a new standard for preventative genetic medicine, backed by the expertise of Nobel Prize winner Jennifer Doudna and other life sciences investors.

The successful pricing of this IPO, coupled with strategic partnerships including those with Eli Lilly and Sanofi, positions Scribe to scale its clinical programs effectively. As the company moves toward the closing of the offering on July 27, 2026, market observers will look to the performance of SCTX in early trading for signs of broader biotech sector momentum. The focus remains on the efficacy of their lead candidate, STX-1150, which represents the company's core technological thesis for transforming cardiovascular health and long-term patient outcomes in a highly competitive sector.